NL9301781A - Ampul en infuusoplossing van thioctzuur in de vorm van de in water oplosbare zouten van thioctzuur. - Google Patents

Ampul en infuusoplossing van thioctzuur in de vorm van de in water oplosbare zouten van thioctzuur. Download PDF

Info

Publication number: NL9301781A
Authority: NL; Netherlands
Prior art keywords: thioctic acid; solution; water; ampoule; soluble salts
Prior art date: 1992-10-15

Application number

NL9301781A

Other languages

English (en)

Dutch (nl)

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-15

Filing date

1993-10-14

Publication date

1994-05-02

1993-10-14 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1994-05-02 Publication of NL9301781A publication Critical patent/NL9301781A/nl

Links

AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title claims description 39
235000019136 lipoic acid Nutrition 0.000 title claims description 36
229960002663 thioctic acid Drugs 0.000 title claims description 36
AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 title claims description 35
150000003839 salts Chemical class 0.000 title claims description 10
239000003708 ampul Substances 0.000 title claims description 8
239000003978 infusion fluid Substances 0.000 title claims description 8
239000003814 drug Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
239000000243 solution Substances 0.000 description 27
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
229910052757 nitrogen Inorganic materials 0.000 description 13
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
239000008215 water for injection Substances 0.000 description 5
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
239000012895 dilution Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
XZUAPPXGIFNDRA-UHFFFAOYSA-N ethane-1,2-diamine;hydrate Chemical compound O.NCCN XZUAPPXGIFNDRA-UHFFFAOYSA-N 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000011109 contamination Methods 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
101000642464 Homo sapiens Spermatogenesis-associated protein 2-like protein Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
206010036106 Polyneuropathy alcoholic Diseases 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
102100030254 Spermatogenesis-associated protein 2 Human genes 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000005263 alkylenediamine group Chemical group 0.000 description 1
150000004716 alpha keto acids Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
201000002342 diabetic polyneuropathy Diseases 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
235000010299 hexamethylene tetramine Nutrition 0.000 description 1
239000004312 hexamethylene tetramine Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
229960004011 methenamine Drugs 0.000 description 1
ZYTYOUNYLKOKAR-UHFFFAOYSA-N morpholine;pyrrolidine Chemical compound C1CCNC1.C1COCCN1 ZYTYOUNYLKOKAR-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NL9301781A 1992-10-15 1993-10-14 Ampul en infuusoplossing van thioctzuur in de vorm van de in water oplosbare zouten van thioctzuur. NL9301781A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE9213914U DE9213914U1 (de)	1992-10-15	1992-10-15	Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure
DE9213914		1992-10-15

Publications (1)

Publication Number	Publication Date
NL9301781A true NL9301781A (nl)	1994-05-02

Family

ID=6884846

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL9301781A NL9301781A (nl)	1992-10-15	1993-10-14	Ampul en infuusoplossing van thioctzuur in de vorm van de in water oplosbare zouten van thioctzuur.

Country Status (7)

Country	Link
BE (1)	BE1007420A3 (it)
DE (1)	DE9213914U1 (it)
ES (1)	ES2063713B1 (it)
FR (1)	FR2696933B3 (it)
IT (1)	IT1260996B (it)
NL (1)	NL9301781A (it)
PT (1)	PT101388B (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4433764A1 (de) *	1994-09-22	1996-03-28	Asta Medica Ag	Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE29506604U1 (de) *	1995-04-25	1995-06-14	Asta Medica Ag, 01277 Dresden	Fertiginfusionsset
ITMI20111975A1 (it) *	2011-10-28	2013-04-29	Labomar S R L	Composizioni comprendenti un sale di un acido organico.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS3922715B1 (it) *	1962-03-29	1964-10-13
JPS4526516B1 (it) *	1968-07-08	1970-09-01
JPS6314940B2 (it) *	1983-09-19	1988-04-02	Kyaraban Kk
EP0318891A1 (de) *	1987-12-04	1989-06-07	ASTA Medica Aktiengesellschaft	Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren
EP0427247A2 (de) *	1989-11-09	1991-05-15	ASTA Medica Aktiengesellschaft	Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1095991B (de) *	1959-05-09	1960-12-29	Chemiewerk Homburg Zweignieder	Verfahren zur Herstellung einer stabilen und injizierbaren 1,2-Dithia-cyclopentan-3-valeriansaeure enthaltenden Loesung
JPS3814940B1 (it) *	1961-03-04	1963-08-15
DE1668887B2 (de) *	1968-03-15	1976-06-16		Ca-salz der 1,2 -dithia-cyclopentan - 3- valerian saeure gleich (thioctsaeure)
IT1213141B (it) *	1984-02-17	1989-12-14	Dobrivoje Tomic	Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
DE3512911A1 (de) *	1985-04-11	1986-10-16	Degussa Ag, 6000 Frankfurt	Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
AT500684B8 (de) *	1989-11-09	2006-11-15	Meda Pharma Gmbh & Co Kg	Verwendung von schwefelhältigen carbonsäuren zur herstellung eines arzneimittels zur bekämpfung von erkrankungen durch retroviren

1992
- 1992-10-15 DE DE9213914U patent/DE9213914U1/de not_active Expired - Lifetime
1993
- 1993-09-03 BE BE9300910A patent/BE1007420A3/fr not_active IP Right Cessation
- 1993-09-16 FR FR9311052A patent/FR2696933B3/fr not_active Expired - Lifetime
- 1993-10-14 NL NL9301781A patent/NL9301781A/nl active Search and Examination
- 1993-10-14 PT PT101388A patent/PT101388B/pt not_active IP Right Cessation
- 1993-10-14 ES ES09302159A patent/ES2063713B1/es not_active Expired - Fee Related
- 1993-10-15 IT ITTO930761A patent/IT1260996B/it active IP Right Grant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS3922715B1 (it) *	1962-03-29	1964-10-13
JPS4526516B1 (it) *	1968-07-08	1970-09-01
JPS6314940B2 (it) *	1983-09-19	1988-04-02	Kyaraban Kk
EP0318891A1 (de) *	1987-12-04	1989-06-07	ASTA Medica Aktiengesellschaft	Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren
EP0427247A2 (de) *	1989-11-09	1991-05-15	ASTA Medica Aktiengesellschaft	Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 6800, Derwent World Patents Index; AN 66-08932F (00) *
DATABASE WPI Week 6800, Derwent World Patents Index; AN 66-14295F (00) *
DATABASE WPI Week 7034, Derwent World Patents Index; AN 70-61064R (34) *

Also Published As

Publication number	Publication date
ES2063713A1 (es)	1995-01-01
PT101388B (pt)	1999-09-30
ES2063713B1 (es)	1995-07-16
ITTO930761A0 (it)	1993-10-15
FR2696933A3 (fr)	1994-04-22
ITTO930761A1 (it)	1995-04-15
PT101388A (pt)	1994-09-30
DE9213914U1 (de)	1992-12-03
IT1260996B (it)	1996-04-29
FR2696933B3 (fr)	1994-09-23
BE1007420A3 (fr)	1995-06-13

Legal Events

Date	Code	Title
1996-06-03	BB	A search report has been drawn up
1996-12-02	BC	A request for examination has been filed
2002-11-01	BN	A decision not to publish the application has become irrevocable

Publication	Publication Date	Title
TW386877B (en)	2000-04-11	Antitumour compositions containing taxane derivatives
Reddy et al.	2008	Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation
TWI238719B (en)	2005-09-01	Moxifloxacin/sodium chloride formulation
CA1188989A (en)	1985-06-18	Nonapeptide for the treatment of drug withdrawal symptoms
JPS58201746A (ja)	1983-11-24	３−ヒドロキシブタン酸またはこの酸から誘導された塩を含有する薬剤組成物、および３−ヒドロキシブタン酸から誘導され、医薬として使用できる化合物
CN102335123A (zh)	2012-02-01	重酒石酸去甲肾上腺素注射液及其制剂工艺
DK2662073T3 (en)	2018-02-12	Octreotide injection
JPS6323888A (ja)	1988-02-01	オキサザホスホリン溶液及びその製造法
US20250090622A1 (en)	2025-03-20	Angiotensin compositions and methods related thereto
GB2165752A (en)	1986-04-23	Bromocriptine compositions
RU2362557C2 (ru)	2009-07-27	Фармацевтическая композиция винфлунина, предназначенная для парентерального введения, способ получения и применение
JP3253302B2 (ja)	2002-02-04	３−ジアルキルアミノエトキシベンゾイル−ベンゾフランを含有する非経口溶液
US11147926B2 (en)	2021-10-19	Intrathecal baclofen pharmaceutical dosage forms and related delivery system
NL9301781A (nl)	1994-05-02	Ampul en infuusoplossing van thioctzuur in de vorm van de in water oplosbare zouten van thioctzuur.
US20060183798A1 (en)	2006-08-17	Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
JP4850426B2 (ja)	2012-01-11	安定な高濃度エダラボン注射液
JP5298028B2 (ja)	2013-09-25	脳虚血障害治療剤
MXPA01006698A (es)	2004-07-30	Solucion de las al monosodica de la n-[o-(p-pivaloiloxibencensulfonilamino)benzoil]glilicina tetrahidratada y producto farmaceutico de la misma.
RU2241488C1 (ru)	2004-12-10	Раствор даларгина для инъекций
DE202012007199U1 (de)	2012-11-07	Intrathekale pharmazeutische Baclofen-Dosierungsformen und dazugehöriges Abgabesystem
US3856964A (en)	1974-12-24	Concentrate for infusion purposes containing 5,5-diphenylhydantoin sodium
JP3103535B2 (ja)	2000-10-30	カルシトニン類のプレフィルドシリンジ製剤
JPH06135852A (ja)	1994-05-17	ウリナスタチン注射液
Weigand et al.	1940	Action and toxicity of vitamin B6 hydrochloride
Madan et al.	1976	Total parenteral nutrition